Analysts Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Price Target at $5.93

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have received a consensus rating of “Hold” from the seven analysts that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $4.94.

Several research analysts have weighed in on the stock. EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th. Robert W. Baird cut shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. Evercore ISI reissued an “in-line” rating and set a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Finally, Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th.

Carisma Therapeutics Price Performance

CARM stock opened at $0.46 on Thursday. Carisma Therapeutics has a 1 year low of $0.38 and a 1 year high of $3.16. The stock has a market capitalization of $19.06 million, a PE ratio of -0.29 and a beta of 1.44. The company’s 50-day moving average is $0.87 and its 200-day moving average is $1.02. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The firm had revenue of $3.39 million during the quarter. Equities research analysts expect that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Carisma Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Carisma Therapeutics by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after acquiring an additional 11,200 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Carisma Therapeutics during the 2nd quarter valued at $40,000. Wexford Capital LP raised its stake in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.